- Home
- UHG vs CYBN Comparison
UHG vs CYBN Comparison
Compare UHG & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- CYBN
- Stock Information
- Founded
- UHG 2004
- CYBN 2019
- Country
- UHG United States
- CYBN Canada
- Employees
- UHG N/A
- CYBN N/A
- Industry
- UHG Homebuilding
- CYBN Pharmaceuticals and Biotechnology
- Sector
- UHG Consumer Discretionary
- CYBN Health Care
- Exchange
- UHG Nasdaq
- CYBN Nasdaq
- Market Cap
- UHG 152.4M
- CYBN 174.9M
- IPO Year
- UHG N/A
- CYBN N/A
- Fundamental
- Price
- UHG $3.31
- CYBN $7.71
- Analyst Decision
- UHG
- CYBN Strong Buy
- Analyst Count
- UHG 0
- CYBN 4
- Target Price
- UHG N/A
- CYBN $86.00
- AVG Volume (30 Days)
- UHG 338.1K
- CYBN 313.2K
- Earning Date
- UHG 08-07-2025
- CYBN 08-07-2025
- Dividend Yield
- UHG N/A
- CYBN N/A
- EPS Growth
- UHG N/A
- CYBN N/A
- EPS
- UHG 0.76
- CYBN N/A
- Revenue
- UHG $449,877,017.00
- CYBN N/A
- Revenue This Year
- UHG N/A
- CYBN N/A
- Revenue Next Year
- UHG N/A
- CYBN N/A
- P/E Ratio
- UHG $4.35
- CYBN N/A
- Revenue Growth
- UHG 5.24
- CYBN N/A
- 52 Week Low
- UHG $1.60
- CYBN $4.81
- 52 Week High
- UHG $6.93
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- UHG 56.38
- CYBN 50.59
- Support Level
- UHG $3.10
- CYBN $7.50
- Resistance Level
- UHG $3.70
- CYBN $9.20
- Average True Range (ATR)
- UHG 0.41
- CYBN 0.56
- MACD
- UHG -0.04
- CYBN -0.12
- Stochastic Oscillator
- UHG 19.54
- CYBN 27.06
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.